Evidence map›Paper›PMID 37120692›Full record

ArticleScientific reports2023

Identification and validation of fatty acid metabolism-related lncRNA signatures as a novel prognostic model for clear cell renal cell carcinoma.

Cheng Shen, Zhan Chen, Jie Jiang, Yong Zhang, Xinfeng Chen, Wei Xu, Rui Peng, Wenjing Zuo, Qian Jiang, Yihui Fan and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Cheng Shen *Department of Urology, The Second Affiliated Hospital of Nantong University, Nantong, 226001, China.
Zhan Chen *Department of Urology, The Second Affiliated Hospital of Nantong University, Nantong, 226001, China.
Jie Jiang *Department of Urology, The Second Affiliated Hospital of Nantong University, Nantong, 226001, China.
Yong ZhangDepartment of Urology, The Second Affiliated Hospital of Nantong University, Nantong, 226001, China.
Xinfeng ChenDepartment of Urology, The Second Affiliated Hospital of Nantong University, Nantong, 226001, China.
Wei XuDepartment of Urology, The Second Affiliated Hospital of Nantong University, Nantong, 226001, China.
Rui PengDepartment of Urology, The Second Affiliated Hospital of Nantong University, Nantong, 226001, China.
Wenjing ZuoDepartment of Orthopedics, The Second Affiliated Hospital of Nantong University, Nantong, China.
Qian JiangDepartment of Paediatric, Chinese Medicine Hospital of Rudong, Nantong, China.
Yihui FanDepartment of Pathogenic Biology, School of Medicine, Nantong University, Nantong, China.
Xingxing FangDepartment of Nephrology, The Second Affiliated Hospital of Nantong University, Nantong, 226001, China. 48776592@qq.com.
Bing ZhengDepartment of Urology, The Second Affiliated Hospital of Nantong University, Nantong, 226001, China. ntzb2008@163.com.
Affiliated Hospital of Nantong University · CNNantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is a main subtype of renal cancer, and advanced ccRCC frequently has poor prognosis. Many studies have found that lipid metabolism influences tumor development and treatment. This study was to examine the prognostic and functional significance of genes associated with lipid metabolism in individuals with ccRCC. Using the database TCGA, differentially expressed genes (DEGs) associated with fatty acid metabolism (FAM) were identified. Prognostic risk score models for genes related to FAM were created using univariate and least absolute shrinkage and selection operator (LASSO) Cox regression analyses. Our findings demonstrate that the prognosis of patients with ccRCC correlate highly with the profiles of FAM-related lncRNAs (AC009166.1, LINC00605, LINC01615, HOXA-AS2, AC103706.1, AC009686.2, AL590094.1, AC093278.2). The prognostic signature can serve as an independent predictive predictor for patients with ccRCC. The predictive signature's diagnostic effectiveness was superior to individual clinicopathological factors. Between the low- and high-risk groups, immunity research revealed a startling difference in terms of cells, function, and checkpoint scores. Chemotherapeutic medications such lapatinib, AZD8055, and WIKI4 had better outcomes for patients in the high-risk group. Overall, the predictive signature can help with clinical selection of immunotherapeutic regimens and chemotherapeutic drugs, improving prognosis prediction for ccRCC patients.

Indexed as

CarcinomaCarcinoma, Renal CellKidney NeoplasmsRNA, Long NoncodingFatty AcidsHumansLipid MetabolismPrognosisFatty AcidsRNA, Long Noncoding

Identifiers

PMID37120692
PMCPMC10148808
OpenAlexW4367367679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.